Ani Pharmaceuticals (ANIP) Revenue (2010 - 2026)

Ani Pharmaceuticals (ANIP) has 17 years of Revenue data on file, last reported at $237.5 million in Q1 2026.

• For the quarter ending Q1 2026, Revenue rose 20.46% year-over-year to $237.5 million; the trailing twelve-month figure through Mar 2026 stood at $923.7 million (up 37.03% YoY), and the FY2025 full-year result was $883.4 million, up 43.78% from the prior year.
• Revenue eased to $237.5 million in Q1 2026, from $247.1 million in the prior quarter.
• In the past five years, Revenue ranged from a high of $247.1 million in Q4 2025 to a low of $64.5 million in Q1 2022.
• A 5-year average of $149.3 million and a median of $137.4 million in 2024 frame the typical range for Revenue.
• Across the five-year window, Revenue soared 475.69% in 2022 and gained 12.52% in 2024, its largest moves.
• Tracing ANIP's Revenue over 5 years: stood at $94.2 million in 2022, then jumped by 39.71% to $131.7 million in 2023, then surged by 44.75% to $190.6 million in 2024, then increased by 29.64% to $247.1 million in 2025, then fell by 3.88% to $237.5 million in 2026.
• Business Quant data shows ANIP's Revenue at $237.5 million in Q1 2026, $247.1 million in Q4 2025, and $227.8 million in Q3 2025.